Van Sanden S - Search Results

1

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: van sanden s. Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23. Curr Med Res Opin. 2021. PMID: 34256668 Clinical Trial.

2

Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.

Van Sanden S, Pisini M, Duchesne I, Mehnert A, Belsey J. Van Sanden S, et al. Curr Med Res Opin. 2016;32(1):147-54. doi: 10.1185/03007995.2015.1106934. Epub 2015 Oct 29. Curr Med Res Opin. 2016. PMID: 26455472

3

Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden.

Thilakarathne P, Diels J, van Sanden S, Liwing J, Van Agthoven M, Chirita O, Nahi H. Thilakarathne P, et al. Among authors: van sanden s, van agthoven m. Value Health. 2014 Nov;17(7):A545-6. doi: 10.1016/j.jval.2014.08.1767. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201764 Free article. No abstract available.

4

Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry.

Thilakarathne P, Diels J, van Sanden S, Liwing J, Chirita O, Van Agthoven M, Nahi H. Thilakarathne P, et al. Among authors: van sanden s, van agthoven m. Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2181. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202162 Free article. No abstract available.

5

Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Sorensen S, Wildgust M, Sengupta N, Trambitas C, Diels J, van Sanden S, Xu Y, Dorman E. Sorensen S, et al. Among authors: van sanden s. Clin Ther. 2017 Jan;39(1):178-189.e5. doi: 10.1016/j.clinthera.2016.12.001. Epub 2017 Jan 3. Clin Ther. 2017. PMID: 28062113 Review.

6

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.

Van Sanden S, Baculea S, Diels J, Cote S. Van Sanden S, et al. Adv Ther. 2017 Jul;34(7):1650-1661. doi: 10.1007/s12325-017-0564-1. Epub 2017 Jun 1. Adv Ther. 2017. PMID: 28573505 Free PMC article.

7

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.

Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A. Van Sanden S, et al. Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192016 Free PMC article.

8

An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.

Traina SB, Slee A, Van Sanden S, Diels J. Traina SB, et al. Among authors: van sanden s. Diabetes Ther. 2018 Feb;9(1):125-140. doi: 10.1007/s13300-017-0343-7. Epub 2017 Dec 13. Diabetes Ther. 2018. PMID: 29236222 Free PMC article.

9

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K. Feyerabend S, et al. Among authors: van sanden s. Eur J Cancer. 2018 Nov;103:78-87. doi: 10.1016/j.ejca.2018.08.010. Epub 2018 Sep 12. Eur J Cancer. 2018. PMID: 30218976 Free article.

10

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.

Feyerabend S, Saad F, Perualila NJ, Van Sanden S, Diels J, Ito T, De Porre P, Fizazi K. Feyerabend S, et al. Among authors: van sanden s. Target Oncol. 2019 Dec;14(6):681-688. doi: 10.1007/s11523-019-00685-x. Target Oncol. 2019. PMID: 31754962 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page